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1. Introduction 
Cardiomyopathies are an important and heterogeneous group of diseases. The awareness 
and knowledge of these diseases in both the public and medical communities historically 
has been impaired by persistent confusion surrounding definitions and nomenclature. 
Classification schemes, of which there have been many, (Thiene et al., 2000, 2004; 
Richardson et al., 1996) are potentially useful in drawing relationships and distinctions 
between complex disease states for the purpose of promoting greater understanding; 
indeed, the precise language used to describe these diseases are profoundly important. 
Cardiomyopathies are diseases of the heart muscle, characterized by abnormality in 
chamber size and wall thickness, or functional contractile dysfunctions mainly systolic or 
diastolic dysfunction in the absence of coronary artery disease, hypertension, valvular 
disease, or congenital heart disease (Elliott et al., 2008). These diseases are classified as 
either primary or secondary. Primary cardiomyopathies consist of disorders solely or 
predominantly confined to the heart muscle, which have genetic, non-genetic, or 
acquired causes. Secondary cardiomyopathies are disorders that have myocardial 
damage as a result of systemic or multiorgan disease (Maron et al., 2006). 
Cardiomyopathies are classified traditionally according to morphological and functional 
criteria into four categories: dilated cardiomyopathy (DCM), hypertrophic 
cardiomyopathy (HCM), restrictive cardiomyopathy (RCM) and arrhythmogenic right 
ventricular cardiomyopathy/dysplasia (ARVC/D). These cardiomyopathies can be 
primary myocardial disorders or develop as a secondary consequence of a variety of 
conditions, including myocardial ischemia, inflammation, infection, increased 
myocardial pressure or volume load and toxic agents. 
The definitions of cardiomyopathies presented here are in concert with the molecular era of 
cardiovascular disease and have direct clinical applications and implications for cardiac 
diagnosis. However, the classification of cardiomyopathies presented herein is not intended 
to provide precise methodologies or strategies for clinical diagnosis. Rather, the 
classification of cardiomyopathies represents a scientific presentation that offers new 
perspectives to aid in understanding this complex and heterogeneous group of diseases and 
basic disease mechanisms. 
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2. Definition 
The term cardiomyopathy was used for the first time in 1957. Over the next 25 years, a number 
of definitions for cardiomyopathies were advanced. Indeed, in the original 1980 WHO 
classification, cardiomyopathies were defined only as “heart muscle diseases of unknown 
cause,” reflecting a general lack of available information about basic disease mechanisms. In 
1968, the WHO defined cardiomyopathies as “diseases of different and often unknown 
etiology in which the dominant feature is cardiomegaly and heart failure.” The final WHO 
classification published in 1995 proposed “diseases of myocardium associated with cardiac 
dysfunction” and included for the first time ARVC/D, as well as primary RCM. 
The American Heart Association (AHA) expert consensus panel proposed definition of 
cardiomyopathies is as follows: “Cardiomyopathies are a heterogeneous group of diseases of 
the myocardium associated with mechanical and/or electrical dysfunction, which usually (but 
not invariably) exhibit inappropriate ventricular hypertrophy or dilatation, due to a variety of 
etiologies that frequently are genetic. Cardiomyopathies are either confined to the heart or are 
part of generalized systemic disorders, and often lead to cardiovascular death or progressive 
heart failure–related disability.” This definition of cardiomyopathies, similar to that reported 
by the European Society of Cardiology (ESC), under the auspices of the Working Group on 
Myocardial and Pericardial Diseases, excludes myocardial involvement secondary to coronary 
artery disease, systemic hypertension, and valvular and congenital heart disease. 
3. Classifications of cardiomyopathies 
Cardiac diseases can have an external cause, such as coronary artery disease, valve disease or 
hypertension, or may involve cardiomyopathies, in which the heart muscle itself is abnormal 
(i.e. an intrinsic cause of the disease is present in the heart muscle). The distinction between 
different classes of cardiac diseases are an important one to make, as cardiac diseases with 
similar phenotypes can have a diverse origin and may need different types of management. 
However, classification of cardiomyopathies is difficult, as the origin or pathophysiology is not 
always understood. Furthermore, at present there is no consensus on how to classify 
cardiomyopathies (e.g., based on origin, physiology or treatment) among clinicians. 
In order to promote a uniform nomenclature and well-defined clinical patient groups, recent 
knowledge on underlying causes and pathophysiology of cardiomyopathies has been 
implemented in a cardiomyopathy classification system both on behalf of the American 
Heart Association (AHA) and of the European Society of Cardiology (ESC). 
The AHA divided cardiomyopathies into 2 major groups based on predominant organ 
involvement. Primary cardiomyopathies (genetic, nongenetic, acquired) are those solely or 
predominantly confined to heart muscle and are relatively few in number (Fig. 1). 
Secondary cardiomyopathies show pathological myocardial involvement as part of a large 
number and variety of generalized systemic (multiorgan) disorders (Table 1). The frequency 
and degree of secondary myocardial involvement vary considerably among these diseases, 
some of which are exceedingly uncommon and for which the evidence of myocardial 
pathology may be sparse and reported in only a few patients. Because many 
cardiomyopathies may predominantly involve the heart but are not necessarily confined to 
that organ, some of the distinctions between primary and secondary cardiomyopathy are 
necessarily arbitrary and inevitably rely on judgment about the clinical importance and 
consequences of the myocardial process (Maron, 2008; Maron et al., 2006). 
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Fig. 1. Classification model for Primary cardiomyopathies (disease processes solely or 
predominantly involves the myocardium). The conditions have been segregated according 
to their genetic or nongenetic etiologies. *Predominantly nongenetic; familial disease with a 
genetic origin has been reported in a minority of cases. ARVC/D indicates arrhythmogenic 
right ventricular cardiomyopathy/dysplasia; CPVT, catecholaminergic polymorphic 
ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; LQTS, long QT syndrome; LVNC, left ventricular noncompaction; SQTS, 
short QT syndrome; and SUNDS, sudden unexplained nocturnal death syndrome. 
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*Accumulation of abnormal substances between myocytes (i.e., extracellular). 
†Genetic (familial) origin. 
‡Accumulation of abnormal substances within myocytes (i.e., intracellular). 
Table 1. Important secondary cardiomyopathies 
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The ESC guidelines are more clinically orientated, which is appealing as this circumvents 
the complex pathophysiology of cardiomyopathies, which is not always comprehended 
upon presentation of the patient. According to the ESC guidelines cardiomyopathies are 
grouped into specific morphological and functional phenotypes; each phenotype is then 
sub-classified into familial and non-familial forms (Fig. 2). In this context, familial refers 
to the occurrence, in more than one family member, of either the same disorder or a 
phenotype that is (or could be) caused by the same genetic mutation and not to acquired 
cardiac or systemic diseases in which the clinical phenotype is influenced by genetic 
polymorphism. Most familial cardiomyopathies are monogenic disorders (i.e., the gene 
defect is sufficient by itself to cause the trait). A monogenic cardiomyopathy can be 
sporadic when the causative mutation is de novo, i.e. has occurred in an individual for the 
first time within the family (or at the germinal level in one of the parents). In this 
classification system, patients with identified de novo mutations are assigned to the 
familial category as their disorder can be subsequently transmitted to their offspring 
(Elliott et al., 2008). Non-familial cardiomyopathies are clinically defined by the presence 
of a cardiomyopathy in the index patient and the absence of disease in other family 
members (based on pedigree analysis and clinical evaluation). They are subdivided into 
idiopathic (no identifiable cause) and acquired cardiomyopathies in which ventricular 
dysfunction is a complication of the disorder rather than an intrinsic feature of the disease 
(Elliott et al., 2008). 
Therefore, on the basis of all these considerations, cardiomyopathies can be most 
effectively classified as primary: genetic, mixed (genetic and nongenetic), acquired; and 
secondary. 
 
 
 
 
 
Fig. 2. Summery of proposed classification. HCM, hypertrophic cardiomyopathy; DCM, 
dilated cardiomyopathy; ARVC, arrhythmogenic right ventricular cardiomyopathy; RCM, 
restrictive cardiomyopathy (*see table 2). 
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ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy;  
HCM, hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy. 
Table 2. Examples of different diseases that cause cardiomyopathies 
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3.1. Primary cardiomyopathies 
3.1.1 Genetic 
3.1.1.1 Hypertrophic cardiomyopathy 
HCM is a condition of the heart in which a part of the myocardium or the muscle of the 
heart is enlarged without any obvious reasons. It is very common and affects people of all 
ages. HCM is a clinically heterogeneous but relatively common autosomal dominant 
genetic heart disease (1:500 of the general population for the disease phenotype 
recognized by echocardiography) that probably is the most frequently occurring 
cardiomyopathy (Maron, 2002). It is the most common cause of sudden cardiac death in 
the young (including trained athletes) and is an important substrate for heart failure 
disability at any age. 
HCM is characterized morphologically and defined by a hypertrophied, nondilated left 
ventricle (LV) in the absence of another systemic or cardiac disease that is capable of 
producing the magnitude of wall thickening evident (e.g., systemic hypertension, aortic 
valve stenosis). Clinical diagnosis is customarily made with 2 dimensional 
echocardiography (or alternatively with cardiac magnetic resonance imaging) by detection 
of otherwise unexplained LV wall thickening, usually in the presence of a small LV cavity, 
after suspicion is raised by the clinical profile or as part of family screening (Maron et al., 
2006). 
When LV wall thickness is mild, differential diagnosis with physiological athlete’s heart 
may arise. Furthermore, individuals harboring a genetic defect for HCM do not necessarily 
express clinical markers of their disease such as LV hypertrophy on echocardiogram, ECG 
abnormalities, or symptoms at all times during life, and ECG alterations can precede the 
appearance of hypertrophy. Indeed, virtually any LV wall thickness, even when within 
normal limits, is consistent with the presence of an HCM-causing mutant gene, and 
diagnosis can be made by laboratory DNA analysis. Furthermore, recognition of LV 
hypertrophy may be age related with its initial appearance delayed well into adulthood 
(adult morphological conversion). Most HCM patients have the propensity to develop 
dynamic obstruction to LV outflow under resting or physiologically provocable conditions, 
produced by systolic anterior motion of the mitral valve with ventricular septal contact 
(Maron et al., 2006). 
HCM is caused by a variety of mutations encoding contractile proteins of the cardiac 
sarcomere. Currently, 11 mutant genes are associated with HCM, most commonly ǃ-myosin 
heavy chain (the first identified) and myosin binding protein C (Barry et al., 2008; Lowey, 
2002). The other 9 genes appear to account for far fewer cases of HCM and include troponin 
T and I, regulatory and essential myosin light chains, titin, ǂ-tropomyosin, ǂ-actin, ǂ-myosin 
heavy chain, and muscle LIM protein (Barry et al., 2008; Selvetella & Lembo, 2005). This 
genetic diversity is compounded by considerable intragenic heterogeneity, with >400 
individual mutations now identified. These most commonly are missense mutations but 
include insertions, deletions, and splice (split-site) mutations encoding truncated sarcomeric 
proteins (Maron et al., 2006). The characteristic diversity of the HCM phenotype is 
attributable to the disease causing mutations and probably to the influence of modifier 
genes and environmental factors. 
In addition, nonsarcomeric protein mutations in 2 genes involved in cardiac metabolism 
have recently been reported to be responsible for primary cardiac glycogen storage diseases 
in older children and adults with a clinical presentation mimicking (or indistinguishable 
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from) that of sarcomeric HCM. One of these conditions involves the gene encoding the Ǆ-2-
regulatory subunit of the AMP-activated protein kinase (PRKAG2), associated with variable 
degrees of LV hypertrophy and ventricular pre-excitation. The other involves the gene 
encoding lysosome-associated membrane protein-2 (LAMP-2), resulting in Danon-type 
storage disease (Maron et al., 2006). Clinical manifestations are limited largely to the heart, 
usually with massive degrees of LV hypertrophy and ventricular pre-excitation. These 
disorders are now part of a subgroup of previously described infiltrative forms of LV 
hypertrophy such as Pompe disease, a glycogen storage disease caused by ǂ-1,4 glycosidase 
(acid maltase deficiency) in infants, and Fabry’s disease, an X-linked recessive disorder of 
glycosphingolipid metabolism caused by a deficiency of the lysosomal enzyme ǂ-
galactosidase A, resulting in intracellular accumulation of glycosphingolipids. Undoubtedly, 
many other mutations causing cardiac hypertrophy by disrupting sarcomere, metabolic, and 
other genes remain to be identified (Elliott et al., 2008). 
A number of other diseases associated with LV hypertrophy involve prominent thickening 
of the LV wall, occurring mostly in infants and children ≤4 years of age, which may 
resemble or mimic typical HCM caused by sarcomere protein mutations. These 
cardiomyopathies include secondary forms such as Noonan syndrome, an autosomal 
dominant cardiofacial condition associated with a variety of cardiac defects (most 
commonly, dysplastic pulmonary valve stenosis and atrial septal defect) resulting from 
mutations in PTPN11, a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2 
genes. At present, the causes of most cases of pediatric cardiomyopathies are unknown 
(Maron et al., 2006). 
Other diseases in this category are mitochondrial myopathies resulting from mutations 
encoding mitochondrial DNA (including Kearns-Sayre syndrome) or mitochondrial proteins 
associated with ATP electron transport chain enzyme defects that alter mitochondrial 
morphology. Also included in these considerations are metabolic myopathies representing 
ATP production and utilization defects involving abnormalities of fatty acid oxidation (acyl 
CoA dehydrogenase deficiencies) and carnitine deficiency, as well as infiltrative 
myopathies, i.e., glycogen storage diseases (type II; autosomal recessive Pompe disease), 
Hunter’s and Hurler’s diseases, and the transient and nonfamilial cardiomyopathy as part of 
generalized organomegaly, recognized in infants of insulin-dependent diabetic mothers. In 
older patients, a number of systemic diseases have been associated with hypertrophic forms 
of cardiomyopathy; these include Friedreich’s ataxia, pheochromocytoma, 
neurofibromatosis, lentiginosis, and tuberous sclerosis. 
3.1.1.2 Arrhythmogenic right ventricular cardiomyopathy/dysplasia 
ARVC/D is predominantly a genetically determined heart muscle disorder that is 
characterized pathologically by fibrofatty replacement of the right ventricular (RV) 
myocardium (Basso et al., 2009). In the early stage of the disease, structural changes may be 
absent or subtle and confined to a localized region of the RV, typically the inflow tract, 
outflow tract, or apex of the RV, the “triangle of dysplasia.” Progression to more diffuse RV 
disease and left ventricular (LV) involvement, typically affecting the posterior lateral wall, is 
common (Marcus et al., 2010). 
ARVC/D is a familial disease in at least 50% of cases and is typically transmitted as an 
autosomal dominant trait with variable penetrance. On the basis of clinical studies and data 
obtained from pre-participation screening for sport activity, the estimated prevalence of the 
disease in the general population ranges from 1 in 1000 to 1 in 5000 (Nava et al., 2000). 
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ARVC/D has a broad clinical spectrum, usually presenting clinically with ventricular 
tachyarrhythmias (e.g., monomorphic ventricular tachycardia). Noninvasive clinical 
diagnosis may be confounding, without an easily obtained single test or finding that is 
definitively diagnostic, and generally requires an integrated assessment of electrical, 
functional, and anatomic abnormalities. Diagnosis often requires a high index of 
suspicion, frequently triggered by presentation with arrhythmias, syncope, or cardiac 
arrest, as well as global or segmental chamber dilatation or wall motion abnormalities 
(Marcus et al., 2010). 
Noninvasive tests used to diagnose ARVC/D, in addition to personal and family history, 
include 12-lead ECG, echocardiography, right ventricular angiography, cardiac magnetic 
resonance imaging, and computerized tomography. Endomyocardial biopsy from the right 
ventricular free wall is a sensitive diagnostic marker when fibrofatty infiltration is 
associated with surviving strands of myocytes. ECGs most commonly show abnormal 
repolarization with T-wave inversion in leads V1 through V3 and small-amplitude potentials 
at the end of the QRS complex (epsilon wave); Brugada syndrome–like right bundle-branch 
block and right precordial ST-segment elevation accompanied by polymorphic ventricular 
tachycardia also have been reported in a small subpopulation of ARVC/D patients (Basso et 
al., 2009; Protonotarios et al., 2011). 
ARVC/D shows autosomal dominant inheritance, albeit often with incomplete 
penetrance. Autosomal dominant ARVC/D has been mapped to 8 chromosomal loci, with 
mutations identified thus far in 4 genes: the cardiac ryanodine receptor RyR2, which is 
also responsible for familial catecholaminergic polymorphic ventricular tachycardia 
(CPVT); desmoplakin; plakophillin-2; and mutations altering regulatory sequences of the 
transforming growth factor-ǃ gene, which has a role in inflammation. Two recessive 
forms have been described in conjunction with palmoplantar keratoderma and woolly 
hair (Naxos disease) and with Carvajal syndrome, caused by mutations in junctional 
plakoglobin and desmoplakin, respectively. Although the function of desmosomal 
proteins to anchor intermediate filaments to desmosomes implicates ARVC/D as a 
primary structural abnormality, there is also a link to ion channel dysfunction (Maron et 
al., 2006). 
3.1.1.3 Left ventricular noncompaction 
Noncompaction of ventricular myocardium is a recently recognized congenital 
cardiomyopathy characterized by a distinctive (“spongy”) morphological appearance of the 
LV myocardium. Noncompaction involves predominantly the distal (apical) portion of the 
LV chamber with deep intertrabecular recesses (sinusoids) in communication with the 
ventricular cavity, resulting from an arrest in the normal embryogenesis (Freedom et al., 
2005). LV noncompaction (LVNC) may be an isolated finding or may be associated with 
other congenital heart anomalies such as complex cyanotic congenital heart disease. 
Diagnosis is made with 2-dimensional echocardiography, cardiac magnetic resonance 
imaging, or LV angiography (Chin et al., 1990). The natural history of LVNC is largely 
unresolved but includes LV systolic dysfunction and heart failure (and some cases of heart 
transplantation), thromboemboli, arrhythmias, sudden death, and diverse forms of 
remodeling. Both familial and nonfamilial cases have been described. In the isolated form of 
LVNC, ZASP (Z-line) and mitochondrial mutations, and X-linked inheritance resulting from 
mutations in the G4.5 gene encoding tafazzin (including association with Barth syndrome in 
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neonates) have been reported. Noncompaction associated with congenital heart disease has 
been shown to result from mutations in the ǂ-dystrobrevin gene and transcription factor 
NKX2.5 (Monserrat Iglesias, 2008). 
3.1.1.4 Conduction system disease 
Lenegre disease, also called as progressive cardiac conduction defect. It is characterized 
by primary progressive development of cardiac conduction defects in the His-Purkinje 
system, leading to widening of the QRS complex, long pauses, and bradycardia that may 
trigger syncope. Phenotypically sick sinus syndrome is similar to progressive cardiac 
conduction defect. Familial occurrence of both syndromes has been reported with an 
autosomal dominant pattern of inheritance. An ion channelopathy, in the form of SCN5A 
mutations, is thought to contribute to these conduction system defects. Wolff-Parkinson-
White syndrome is familial in some cases, but information about the genetic causes is 
unavailable. 
3.1.1.5 Ion channelopathies 
There is a growing list of uncommon inherited and congenital arrhythmia disorders caused 
by mutations in genes encoding defective ionic channel proteins, governing cell membrane 
transit of sodium and potassium ions (Aleong et al., 2007). These ion channel disorders 
include LQTS, short-QT syndrome (SQTS), Brugada syndrome, and CPVT. Nocturnal 
sudden unexplained death syndrome in young Southeast Asian males and Brugada 
syndrome are based on similar clinical and genetic profiles. A small proportion (5% to 10%) 
of sudden infant deaths also may be linked to ion channelopathies, including LQTS, SQTS, 
and Brugada syndrome (Modell & Lehmann, 2006). Clinical diagnosis of the ion 
channelopathies often can be made by identification of the disease phenotype on standard 
12-lead ECG. Some of these cases had previously been classified as idiopathic ventricular 
fibrillation, a description that persists for a syndrome in which mechanistic understanding is 
lacking (Aleong et al., 2007; Kass, 2005). 
3.1.1.5.1 Long-QT syndrome 
This is the most common condition of the ion channelopathies. It is characterized by 
prolongation of ventricular repolarization and QT interval (corrected for heart rate) on the 
standard 12-lead ECG, a specific form of polymorphic ventricular tachycardia (torsade des 
pointes), and a risk for syncope and sudden cardiac death. Phenotypic expression (on the 
ECG) varies considerably, and ~25% to 50% of affected family members may show 
borderline or even normal QT intervals. 
Two patterns of inheritance have been described in LQTS: a rare autosomal recessive disease 
associated with deafness (Jervell and Lange-Nielsen syndrome), which is caused by 2 genes 
that encode for the slowly activating delayed rectifier potassium channel (KCNQ1 and 
KCNE1 (minK)), and the much more common autosomal dominant disease unassociated 
with deafness (Romano-Ward syndrome), which is caused by mutations in 8 different genes. 
These include KCNQ1 (KvLQT1, LQT1), KCNH2 (HERG, LQT2), SCN5A (Na1.5, LQT3), 
ANKB (LQT4), KCNE1 (minK, LQT5), KCNE2 (MiRP1, LQT6), KCNJ2 (Kir2.1, LQT7, 
Andersen’s syndrome), and CACNA1C (Ca1.2, LQT8, Timothy syndrome). Of the 8 genes, 6 
encode for cardiac potassium channels, 1 for the sodium channel (SCN5A, LQT3), and 1 for 
the protein ankyrin, which is involved in anchoring ion channels to the cellular membrane 
(ANKB) (Maron et al., 2006). 
www.intechopen.com
 Classification and Definitions of Cardiomyopathies 
 
13 
3.1.1.5.2 Brugada syndrome 
This syndrome is a relatively new clinical entity associated with sudden cardiac death in 
young people. First described in 1992, the syndrome is identified by a distinctive ECG 
pattern consisting of right bundle-branch block and coved ST-segment elevation in the 
anterior pre-cordial leads (V1 through V3). The characteristic ECG pattern is often concealed 
and may be unmasked with the administration of sodium channel blockers, including 
ajmaline, flecainide, procainamide, and pilsicainide. Familial autosomal dominant and 
sporadic forms have been linked to mutations in an ǂ-subunit of the cardiac sodium channel 
gene SCN5A (the same gene responsible for LQT3) in 20% of patients. Another locus has 
been reported on the short arm of chromosome 3, but no gene has been identified. Sudden 
unexplained nocturnal death syndrome, found predominantly in young Southeast Asian 
males (i.e., those from Thailand, Japan, the Philippines, and Cambodia), is a disorder 
causing sudden death during sleep as a result of ventricular tachycardia/fibrillation. Some 
cases of sudden unexplained nocturnal death syndrome resulting from SCN5A gene 
mutations and Brugada syndrome have been shown to be phenotypically, genetically, and 
functionally the same disorder (Antzelevitch et al., 2005; Krittayaphong et al., 2003). 
3.1.1.5.3 Catecholaminergic polymorphic ventricular tachycardia 
CPVT is characterized by syncope, sudden death, polymorphic ventricular tachycardia 
triggered by vigorous physical exertion or acute emotion (usually in children and 
adolescents), a normal resting ECG, and the absence of structural cardiac disease. Family 
history of 1 or multiple sudden cardiac deaths are evident in 30% of cases. The resting ECG 
is unremarkable, except for sinus bradycardia and prominent U waves in some patients. The 
most typical arrhythmia of CPVT is bidirectional ventricular tachycardia presenting with an 
alternating QRS axis. The autosomal dominant form of the disease has been linked to the 
RyR2 gene encoding for the cardiac ryanodine receptor, a large protein that forms the Ca2+ 
release channel in the sarcoplasmic reticulum that is essential for regulation of excitation-
contraction coupling and [Ca2+]i levels. An autosomal recessive form has been linked to 
CASQ2, a gene that encodes for calsequestrin, a protein that serves as a major Ca2+-binding 
protein in the terminal cisternae of the sarcoplasmic reticulum. Calsequestrin is bound to the 
ryanodine receptor and participates in the control of excitation-contraction coupling (Wilde 
et al., 2008). 
3.1.1.5.4 Short-QT syndrome 
First described in 2000, the SQTS is characterized by a short QT interval (<330 ms) on an 
ECG and a high incidence of sudden cardiac death resulting from ventricular 
tachycardia/fibrillation. Another distinctive ECG feature of SQTS is the appearance of tall 
peaked T waves similar to those encountered with hyperkalemia. The syndrome has been 
linked to gain-of-function mutations in KCNH2 (HERG, SQT1), KCNQ1 (KvLQT1, SQT2), 
and KCNJ2 (Kir2.1, SQT3), causing an increase in the intensity of Ikr, Iks and Ikl, respectively 
(Gaita et al., 2003; Schimpf et al., 2005). 
3.1.1.5.5 Idiopathic ventricular fibrillation 
A subgroup of patients with sudden death appears in the literature with the designation of 
idiopathic ventricular fibrillation. However, it is likely that idiopathic ventricular fibrillation 
is not an independent disease entity but rather a conglomeration of conditions with normal 
gross and microscopic findings in which arrhythmic risk undoubtedly derives from 
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molecular abnormalities, most likely ion channel mutations. At present, insufficient data are 
available to permit the classification of idiopathic ventricular fibrillation as a distinct 
cardiomyopathy (Chen et al., 1998). 
3.1.2 Mixed (genetic and nongenetic) 
3.1.2.1 Dilated cardiomyopathy 
DCM is the most common cardiomyopathy worldwide and has many causes. It is a heart 
muscle disorder defined by the presence of a dilated and poorly functioning left or both 
ventricles. It can be primary (genetic, mixed or predominantly familial non-genetic, or 
acquired) or secondary (e.g., infiltrative or autoimmune). This disease can be diagnosed in 
association with recognized cardiovascular disease; however, to qualify as DCM, the extent 
of myocardial dysfunction cannot be explained exclusively by abnormal loading conditions 
(hypertension, valve disease) or ischaemic heart disease (Elliott et al., 2008; Jefferies & 
Towbin, 2010). A large number of cardiac and systemic diseases can cause systolic 
impairment and left ventricular dilatation, but in the majority of patients no identifiable 
cause is found hence the term “idiopathic” dilated cardiomyopathy (IDC). There are 
experimental and clinical data in animals and humans suggesting that genetic, viral, and 
immune factors contribute to the pathophysiology of IDC (Elliott, 2000). DCM is associated 
with sudden cardiac death and heart failure, resulting in a large cost burden because of the 
very high rate of hospital admission and the potential need for heart transplantation. 
DCM is characterized mainly by left ventricular systolic (or diastolic in some case) 
dysfunction (abnormality of contraction), with an associated increase in mass and volume. 
Right ventricular dilation and dysfunction can also develop but are not needed for 
diagnosis. Prevalence in the general population remains undefined. This disorder develops 
at any age, in either sex, and in people of any ethnic origin (Rosamond et al., 2008; Towbin 
et al., 2006). In adults, DCM arises more commonly in men than in women. In children, the 
yearly incidence is 0.57 cases per 100000 per year overall, but is higher in boys than in girls 
(0.66 vs. 0.47 cases per 100000, P<0.006), in black people than in white people (0.98 vs. 0.46 
cases per 100000, P<0.001), and in babies younger than 1 year than in children (4.40 vs. 0.34 
cases per 100000, P<0.001). Two thirds of children are thought to have idiopathic disease 
(Towbin et al., 2006). In adults, the prevalence is 1 in 2500 individuals, with an incidence of 7 
per 100000 per year (but it could be underdiagnosed). In many cases, the disease is 
inherited, and is called familial dilated cardiomyopathy (FDC). The familial type might 
account for 20-48% of all cases (Taylor et al., 2006). To achieve improved care and outcomes 
in children and adults, a broadened understanding of the causes of these disorders are 
needed. 
In this disease, the left ventricle is dilated, and more spherical than usual with raised wall 
stress and depressed systolic function. Mitral regurgitation, thromboembolic events and 
ventricular arrhythmias can also develop. Occasionally, other rhythm disturbances such as 
atrioventricular block, supraventricular tachycardia with or without pre-excitation including 
Wolf-Parkinson-White syndrome and atrial fibrillation develop. In the most severe cases, 
affected individuals present with signs and symptoms of HF–diaphoresis, breathlessness at 
rest or with exertion, orthopnoea, exercise intolerance, early onset fatigue, abdominal pain, 
and pallor. Cachexia and peripheral oedema typically arise late in the course of the disease. 
Young children often have poor appetite and cachexia, similar to adults. Sinus tachycardia, 
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gallop rhythm, jugular-venous distention, pallor, cool hands and feet, hepatomegaly, and a 
murmur that is consistent with mitral regurgitation are common findings at physical 
examination (Jefferies & Towbin, 2010; Luk et al., 2009). Additionally, peripheral oedema and 
ascites are late signs in children. DCM can occur in a number of X-linked diseases such as 
Becker’s and Duchenne’s muscular dystrophies. It may also occur in patients with 
mitochondrial DNA mutations and inherited metabolic disorders. Thus when taking a family 
history, specific attention should be given to a history of muscular dystrophy, features of 
mitochondrial disease (for example, familial diabetes, deafness, epilepsy, maternal 
inheritance), and signs and symptoms of other inherited metabolic diseases (Elliott, 2000) 
About 20-48% of DCM have been reported as familial, although with incomplete and age-
dependent penetrance, and linked to a diverse group of >20 loci and genes ((Taylor et al., 
2006)). Although genetically heterogeneous, the predominant mode of inheritance for DCM 
is autosomal dominant, with X-linked autosomal recessive and mitochondrial inheritance 
less frequent. Several of the mutant genes linked to autosomal dominant DCM encode the 
same contractile sarcomeric proteins that are responsible for HCM, including ǂ-cardiac 
actin; ǂ-tropomyosin; cardiac troponin T, I, and C; ǃ- and ǂ-myosin heavy chain; and 
myosin binding protein C. Z-disc protein-encoding genes, including muscle LIM protein, ǂ-
actinin-2, ZASP, and titin, also have been identified. 
DCM is also caused by a number of mutations in other genes encoding 
cytoskeletal/sarcolemmal, nuclear envelope, sarcomere, and transcriptional coactivator 
proteins. The most common of these probably is the lamin A/C gene, also associated 
with conduction system disease, which encodes a nuclear envelope intermediate filament 
protein. Mutations in this gene also cause Emery-Dreifuss muscular dystrophy. The X-
linked gene responsible for Emery-Dreifuss muscular dystrophy, emerin (another 
nuclear lamin protein), also causes similar clinical features. Other DCM genes of this 
type include desmin, caveolin, and ǃ- and ǂ-sarcoglycan, as well as the mitochondrial 
respiratory chain gene. X-linked DCM is caused by the Duchenne muscular dystrophy 
(dystrophin) gene, whereas G4.5 (tafazzin), a mitochondrial protein of unknown 
function, causes Barth syndrome, which is an X-linked cardioskeletal myopathy in 
infants (Maron et al., 2006). 
3.1.2.2 Restrictive cardiomyopathy 
RCM is defined as heart-muscle disease that results in impaired ventricular filling, with 
normal or decreased diastolic volume of either or both ventricles. Systolic function usually 
remains normal, at least early in the disease, and wall thickness may be normal or increased, 
depending on the underlying cause (Kushwaha et al., 1997). 
The exact prevalence of RCM is unknown but it is probably the least common type of 
cardiomyopathy. RCM may be idiopathic, familial, or result from various systemic 
disorders, in particular, amyloidosis, sarcoidosis, carcinoid heart disease, scleroderma and 
anthracycline toxicity. Familial RCM is often characterized by autosomal dominant 
inheritance, which in some families is caused by mutations in the troponin I gene; in others, 
familial RCM is associated with conduction defects, caused by mutations in the desmin gene 
(usually associated with skeletal myopathy) (Fitzpatrick et al., 1990). Rarely, familial disease 
can be associated with autosomal recessive inheritance (such as haemochromatosis caused 
by mutations in the HFE gene, or glycogen storage disease), or with X-linked inheritance 
(such as Anderson–Fabry disease) (Elliott et al., 2008). 
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RCM can also be caused by endocardial pathology (fibrosis, fibroelastosis, and thrombosis) 
that impairs diastolic function. These disorders can be sub-classified according to the 
presence of eosinophilia into endomyocardial diseases with hypereosinophilia (e.g., 
hypereosinophilic syndromes (HES)) and endomyocardial disease without 
hypereosinophilia (e.g., endomyocardial fibrosis (EMF)) (Fauci et al., 1982). Parasitic 
infections, drugs such as methysergide, and inflammatory and nutritional factors have been 
implicated in acquired forms of EMF. Fibrous endocardial lesions of the right and/or left 
ventricular inflow tract cause incompetence of the atrioventricular valves (Kushwaha et al., 
1997). Isolated left ventricular involvement results in pulmonary congestion and 
predominant right ventricular involvement leads to right heart failure.  
3.1.3 Acquired 
3.1.3.1 Myocarditis (inflammatory cardiomyopathy) 
Myocarditis is an acute or a chronic inflammatory process affecting the myocardium 
produced by a wide variety of toxins and drugs (e.g., cocaine, interleukin 2) or infectious 
agents, most commonly including viral (e.g., coxsackievirus, adenovirus, parvovirus, 
HIV), bacterial (e.g., diphtheria, meningococcus, psittacosis, streptococcus), rickettsial 
(e.g., typhus, Rocky Mountain spotted fever), fungal (e.g., aspergillosis, candidiasis), and 
parasitic (Chagas disease, toxoplasmosis), as well as Whipple disease (intestinal 
lipodystrophy), giant cell myocarditis, and hypersensitivity reactions to drugs such as 
antibiotics, sulfonamides, anticonvulsants, and anti-inflammatories. Endocardial 
fibroelastosis is a DCM in infants and children that is a consequence of viral myocarditis 
in utero (mumps) (Maron et al., 2006). 
Myocarditis typically evolves through active, healing, and healed stages. It is 
characterized progressively by inflammatory cell infiltrates leading to interstitial edema 
and focal myocyte necrosis and ultimately replacement fibrosis (Calabrese & Thiene, 
2003). These pathological processes create an electrically unstable substrate predisposing 
to the development of ventricular tachyarrhythmias. In some instances, an episode of viral 
myocarditis (frequently subclinical) can trigger an autoimmune reaction that causes 
immunologic damage to the myocardium or cytoskeletal disruption, culminating in DCM 
with LV dysfunction. Evidence for the evolution of myocarditis to DCM comes from 
several sources, including animal models, the finding of inflammatory infiltrates and 
persistence of viral RNA in endomyocardial biopsies from patients with DCM, and the 
natural history of patients with selected conditions such as Chagas disease. The list of 
agents responsible for inflammatory myocarditis overlaps with that of the infectious 
origin of DCM, thereby underscoring the potential interrelationship between the 2 
conditions (Cooper, 2009). 
Myocarditis can be diagnosed by established histopathological, histochemical, or molecular 
criteria, but it is challenging to identify clinically. Suspicion may be raised by chest pain, 
exertional dyspnea, fatigue, syncope, palpitations, ventricular tachyarrhythmias, and 
conduction abnormalities or by acute congestive heart failure or cardiogenic shock 
associated with LV dilatation and/or segmental wall motion abnormalities and ST-T 
changes on ECG. When myocarditis is suspected from the clinical profile, an 
endomyocardial biopsy may resolve an otherwise ambiguous situation by virtue of 
diagnostic inflammatory (leukocyte) infiltrate and necrosis (i.e., the Dallas criteria) but also 
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is limited by insensitivity and false-negative histological results. The diagnostic yield of 
myocardial biopsies can be enhanced substantially by molecular analysis with DNA-RNA 
extraction and polymerase chain reaction amplification of the viral genome. In addition to 
the inflammatory process, viral genome encoded proteases appear to disrupt the 
cytoskeletal sarcomeric linkages of cardiomyocytes (Calabrese & Thiene, 2003; Parrillo, 
2001). 
3.1.3.2 Stress (“Tako-Tsubo”) cardiomyopathy 
Stress cardiomyopathy, first reported in Japan as “takotsubo,” is a recently described clinical 
entity characterized by acute but rapidly reversible LV systolic dysfunction in the absence of 
atherosclerotic coronary artery disease, triggered by profound psychological stress (Sealove 
et al., 2008; Sharkey et al., 2005). This distinctive form of ventricular stunning typically 
affects older women and preferentially involves the distal portion of the LV chamber 
(“apical ballooning”), with the basal LV hypercontractile. Although presentation often 
mimics ST-segment–elevation myocardial infarction, outcome is favorable with appropriate 
medical therapy. 
3.2 Secondary cardiomyopathies 
The most important secondary cardiomyopathies are provided in the Table 1. This list, 
however, is not intended to represent an exhaustive and complete tabulation of the vast 
number of systemic conditions reported to involve the myocardium. Rather, it is limited to 
the most common of these diseases most consistently associated with a cardiomyopathy. 
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